Dentatorubral Pallidoluysian Atrophy (Drpla) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Dentatorubral-pallidoluysian atrophy (DRPLA) is a rare, autosomal dominant neurodegenerative disorder caused by an expanded CAG [trinucleotide repeat] in the [ATN1[/genes/[atn1[/genes/[atn1[/genes/[atn1--TEMP--/genes)--FIX-- gene encoding the atrophin-1 protein. DRPLA belongs to the family of [polyglutamine[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases--TEMP--/mechanisms)--FIX-- (polyQ) repeat expansion diseases alongside [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, [spinocerebellar ataxias], and [Kennedy's disease (SBMA)[/diseases/[kennedys-disease[/diseases/[kennedys-disease[/diseases/[kennedys-disease--TEMP--/diseases)--FIX--. The disease is characterized by progressive cerebellar ataxia, choreoathetosis, myoclonus, epilepsy, cognitive decline, and psychiatric disturbances (Kanazawa, 1999).
DRPLA was first described by Smith and colleagues in 1958, though the genetic basis was not identified until 1994 when Koide et al. and Nagafuchi et al. independently discovered the causative [CAG repeat expansion] in [ATN1[/genes/[atn1[/genes/[atn1[/genes/[atn1--TEMP--/genes)--FIX--. The disorder is particularly prevalent in Japan, where it accounts for 7–20% of autosomal dominant cerebellar ataxias.
DRPLA shows striking geographic variation in prevalence:
- Japan: The most commonly affected population, with a prevalence of approximately 0.2–0.7 per 100,000. [DRPLA accounts for 7–20% of autosomal dominant [spinocerebellar ataxias[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia--TEMP--/diseases)--FIX-- in Japan (GeneReviews).
- Other Asian populations: Lower but notable rates — Singapore (~6%), Korea (~3%) of SCA cohorts (Tsuji, 2012)
- Europe: 0.25–1% of SCA cohorts in most European populations, with higher rates (2–4%) in Portuguese families
- Latin America: 0.14–3.1% of SCA cohorts
The higher prevalence in Japan is attributed to a larger pool of intermediate-length (20–35 repeats) [ATN1[/genes/[atn1[/genes/[atn1[/genes/[atn1--TEMP--/genes)--FIX-- alleles in the Japanese population, which are more prone to pathogenic expansion. The mean age of onset is 31.5 years, with a remarkable range from infancy to 72 years, inversely correlated with CAG repeat length.
DRPLA displays marked phenotypic variability depending on the age of onset, which is inversely related to the CAG repeat length.
The juvenile form is characterized by:
- Progressive myoclonus epilepsy with generalized seizures
- Cerebellar ataxia
- Intellectual disability and progressive cognitive decline
- Myoclonus
- Choreoathetosis
- Behavioral disturbances
This form progresses rapidly and is often associated with very large [CAG repeat expansion[/mechanisms/[cag-repeat-expansion[/mechanisms/[cag-repeat-expansion[/mechanisms/[cag-repeat-expansion--TEMP--/mechanisms)--FIX--s (>65 repeats). Seizures may be intractable and are a major source of morbidity.
The adult form presents with:
- Cerebellar ataxia (gait and limb ataxia, dysarthria)
- Choreoathetosis and other involuntary movements
- Dementia and progressive cognitive decline
- Psychiatric symptoms (depression, psychosis, behavioral changes)
- Myoclonus
Epilepsy is less prominent in the adult-onset form. The clinical picture may initially resemble [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- due to the combination of chorea and cognitive decline, leading to potential misdiagnosis.
Late-onset DRPLA presents primarily with a cerebellar-predominant phenotype, reflecting the shorter CAG repeat lengths (49-55 repeats) typically associated with adult disease (Koide et al., 1994):
- Cerebellar ataxia: Progressive gait and limb ataxia with dysarthria; the dominant clinical feature
- Cognitive decline: Mild cognitive impairment progressing to subcortical dementia over decades
- Reduced involuntary movements: Chorea and myoclonus are less prominent compared to juvenile-onset forms
- Psychiatric features: Depression, personality changes, and emotional lability
- Progression: Slower than juvenile-onset disease, with survival often extending 10-20+ years from symptom onset
- Differential diagnosis: Often misdiagnosed as [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- or [Spinocerebellar Ataxia[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia--TEMP--/diseases)--FIX-- due to overlapping features
¶ [ATN1[/genes/[atn1[/genes/[atn1[/genes/[atn1--TEMP--/genes)--FIX-- Gene and CAG Repeat Expansion
DRPLA is caused by expansion of a CAG trinucleotide repeat in the [ATN1[/genes/[atn1[/genes/[atn1[/genes/[atn1--TEMP--/genes)--FIX-- gene (chromosome 12p13.31), which encodes the atrophin-1 protein. The repeat length determines disease status:
| Repeat Length |
Classification |
| 6–35 repeats |
Normal |
| 36–47 repeats |
Intermediate/reduced penetrance |
| ≥48 repeats |
Full penetrance (disease-causing) |
The expanded CAG repeat is translated into an elongated [polyglutamine[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases--TEMP--/mechanisms)--FIX-- tract in the atrophin-1 protein, leading to protein misfolding, aggregation, and neuronal toxicity.
DRPLA demonstrates the most prominent genetic anticipation among all CAG repeat disorders. Anticipation refers to earlier onset and increased severity in successive generations due to intergenerational repeat instability:
- Paternal transmission: In 80% of paternal transmissions, the repeat expands by more than 5 repeats, leading to dramatically earlier onset in offspring (Ikeuchi et al., 1995)
- Maternal transmission: All maternal transmissions show either a decrease or an increase of fewer than 5 repeats
- A father with adult-onset DRPLA may have a child with severe juvenile-onset disease due to large intergenerational repeat expansion
The CAG repeat length inversely correlates with age of onset and influences clinical phenotype:
- Longer repeats → earlier onset → more likely progressive myoclonus epilepsy phenotype
- Shorter repeats → later onset → more likely cerebellar ataxia-choreoathetosis phenotype
Atrophin-1 is a 1,184 amino acid protein widely expressed in the central nervous system. Its normal function involves transcriptional regulation through interactions with nuclear receptor corepressors. The expanded [polyglutamine[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases--TEMP--/mechanisms)--FIX-- tract causes the protein to misfold and form intranuclear inclusions in affected [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- (Nowak et al., 2023).
Similar to other [polyglutamine diseases], [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- in DRPLA accumulate intranuclear inclusions containing:
- Mutant atrophin-1 with expanded [polyglutamine[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases--TEMP--/mechanisms)--FIX-- tract
- [Ubiquitin]
- Components of the [proteasome] system
- Transcription factors and coactivators
The diffuse accumulation of mutant atrophin-1 in neuronal nuclei, rather than just the inclusions themselves, may be the primary toxic species.
Mutant atrophin-1 disrupts normal gene transcription through multiple mechanisms:
- Sequestration of CREB-binding protein (CBP) and other transcriptional coactivators into nuclear inclusions
- Disruption of CREB-dependent transcription pathways
- Altered chromatin architecture through aberrant interactions with [histone deacetylases (HDACs)[/entities/[histone-deacetylase[/entities/[histone-deacetylase[/entities/[histone-deacetylase--TEMP--/entities)--FIX--
- Interference with nuclear receptor-mediated signaling (Nowak et al., 2023)
The hallmark neuropathological feature is combined degeneration of the dentatorubral and pallidoluysian systems:
- Dentatorubral system: Degeneration of the dentate nucleus of the [cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum[/brain-regions/[cerebellum--TEMP--/brain-regions)--FIX-- and the red nucleus of the midbrain
- Pallidoluysian system: Degeneration of the globus pallidus (external segment) and the subthalamic nucleus (corpus Luysii) of the [basal ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia[/brain-regions/[basal-ganglia--TEMP--/brain-regions)--FIX--
- Additional involvement: cerebral white matter, [cerebral [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, and brainstem structures
The pattern of neurodegeneration explains the clinical features: cerebellar degeneration causes ataxia, [basal ganglia[/entities/[basal-ganglia[/entities/[basal-ganglia[/entities/[basal-ganglia--TEMP--/entities)--FIX-- involvement causes chorea and other movement disorders, and cortical/white matter changes contribute to cognitive decline.
DRPLA should be considered in patients presenting with:
- Progressive cerebellar ataxia with chorea or myoclonus
- Family history consistent with autosomal dominant inheritance
- Progressive myoclonus epilepsy (particularly in juvenile cases)
- Cognitive decline disproportionate to age
Definitive diagnosis is made by molecular genetic testing demonstrating ≥48 CAG repeats in the [ATN1[/genes/[atn1[/genes/[atn1[/genes/[atn1--TEMP--/genes)--FIX-- gene. Commercial genetic testing is widely available. Testing can confirm the diagnosis, estimate prognosis based on repeat length, and identify at-risk family members.
- MRI: Progressive cerebellar and brainstem atrophy. Cerebral white matter changes (leukoencephalopathy) are common, especially in juvenile-onset cases
- MR spectroscopy: May show reduced N-acetylaspartate (NAA) in the [cerebellum[/entities/[cerebellum[/entities/[cerebellum[/entities/[cerebellum--TEMP--/entities)--FIX-- and brainstem
DRPLA must be distinguished from:
- [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- — chorea and cognitive decline, but different gene and repeat
- Other [spinocerebellar ataxias] — particularly SCA types 1, 2, 3, 6, 7, and 17
- [Myotonic dystrophy[/diseases/[myotonic-dystrophy[/diseases/[myotonic-dystrophy[/diseases/[myotonic-dystrophy--TEMP--/diseases)--FIX-- — another trinucleotide repeat disorder
- Progressive myoclonus epilepsies (Unverricht-Lundborg, Lafora) in juvenile cases
- [Friedreich's Ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia--TEMP--/diseases)--FIX-- — autosomal recessive ataxia
¶ Treatment and Management
There is no disease-modifying treatment for DRPLA. Management is supportive and symptomatic:
- Epilepsy: Antiseizure medications (valproic acid, levetiracetam, clonazepam). Seizures in juvenile DRPLA may be refractory to treatment
- Chorea and movement disorders: Dopamine-depleting agents (tetrabenazine) or dopamine receptor blockers may help
- Ataxia: Physical therapy, occupational therapy, and assistive devices for mobility
- Cognitive decline: Cognitive rehabilitation and supportive care
- Psychiatric symptoms: Antidepressants, antipsychotics as indicated
- Nutritional support: Dysphagia management, dietary counseling
Genetic counseling is essential for affected families due to the complexities of repeat instability and anticipation in DRPLA (Ikeuchi et al., 1995):
- Predictive testing: At-risk family members can undergo predictive genetic testing for the CAG expansion; psychological counseling before and after testing is recommended per international guidelines
- Anticipation counseling: Families must be informed that paternal transmission carries a high risk of repeat expansion, potentially leading to earlier onset and more severe juvenile-onset disease in offspring
- Prenatal diagnosis: Available via chorionic villus sampling (CVS) or amniocentesis; preimplantation genetic testing (PGT) can be offered for in vitro fertilization
- Intermediate alleles: Individuals with 36-47 CAG repeats may not develop disease themselves but can transmit expanded alleles to offspring through intergenerational instability
- Ethical considerations: Given the lack of disease-modifying therapy, predictive testing follows protocols similar to [Huntington's Disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, emphasizing informed consent, psychological readiness, and post-test support
Several approaches are being investigated for [polyglutamine diseases[/mechanisms/[[polyglutamine[/mechanisms/[polyglutamine-diseases[/mechanisms/[[polyglutamine--TEMP--/mechanisms/polyglutamine-diseases[//mechanisms//mechanisms/[polyglutamine-diseases--TEMP--//mechanisms//mechanisms/[polyglutamine[//mechanisms//mechanisms//mechanisms/[polyglutamine-diseases--TEMP--//mechanisms//mechanisms/[polyglutamine[//mechanisms//mechanisms//mechanisms/[polyglutamine-diseases](//mechanisms//mechanisms/polyglutamine-diseases](//mechanisms//mechanisms/[polyglutamine](//mechanisms//mechanisms//mechanisms/polyglutamine-diseases](//mechanisms//mechanisms/[polyglutamine](/mechanisms//mechanisms//mechanisms//mechanisms/polyglutamine-diseases](//mechanisms//mechanisms//mechanisms/polyglutamine-diseases](//mechanisms//mechanisms/polyglutamine-diseases](//mechanisms//mechanisms/[polyglutamine](//mechanisms//mechanisms//mechanisms/polyglutamine-diseases](//mechanisms//mechanisms/polyglutamine (//mechanisms//mechanisms)--FIX-- (/mechanisms//mechanisms/polyglutamine-diseases) ()--FIX-- (/mechanisms/polyglutamine-diseases) ()--FIX---diseases) including DRPLA:
- [Antisense oligonucleotides (ASOs)[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy--TEMP--/treatments)--FIX--: Gene silencing strategies targeting mutant [ATN1[/genes/[atn1[/genes/[atn1[/genes/[atn1--TEMP--/genes)--FIX-- mRNA, analogous to approaches being developed for [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--
- [HDAC] inhibitors: Targeting transcriptional dysregulation caused by mutant atrophin-1
- [autophagy[/entities/[autophagy[/entities/[autophagy[/entities/[autophagy--TEMP--/entities)--FIX-- enhancement: Strategies to promote clearance of mutant protein aggregates via the [autophagy-lysosomal pathway[/mechanisms/[autophagy-lysosomal-pathway[/mechanisms/[autophagy-lysosomal-pathway[/mechanisms/[autophagy-lysosomal-pathway--TEMP--/mechanisms)--FIX--
- Proteasome modulators: Enhancing [ubiquitin-[proteasome[/entities/[proteasome[/entities/[proteasome[/entities/[proteasome--TEMP--/entities)--FIX-- system] capacity to degrade mutant atrophin-1
Efforts to identify fluid and imaging biomarkers for DRPLA are ongoing to enable clinical trial readiness. [Neurofilament light chain ([NfL[/entities/[neurofilament-light[/entities/[neurofilament-light[/entities/[neurofilament-light--TEMP--/entities)--FIX-- levels in cerebrospinal fluid and blood are being evaluated as potential markers of neuronal injury and disease progression (Giunti et al., 2021).
- Drosophila models: Recent Drosophila models expressing expanded atrophin-1 have provided insights into pathogenic mechanisms including nuclear aggregation and transcriptional dysregulation (Sahebi et al., 2025)
- Mouse models: Transgenic mice expressing expanded [ATN1[/genes/[atn1[/genes/[atn1[/genes/[atn1--TEMP--/genes)--FIX-- recapitulate key features including ataxia, seizures, and intranuclear inclusions
- iPSC-derived neuronal models: Patient-derived induced pluripotent stem cells are being used for drug screening and mechanistic studies
- [Antisense Oligonucleotide Therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy[/treatments/[antisense-oligonucleotide-therapy--TEMP--/treatments)--FIX--
- [All Diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases
The study of Dentatorubral Pallidoluysian Atrophy (Drpla) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
DRPLA is a rare but clinically important [polyglutamine[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases--TEMP--/mechanisms)--FIX-- repeat expansion disorder that shares mechanistic features with [Huntington's Disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- and other [spinocerebellar ataxias[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia--TEMP--/diseases)--FIX--. The correlation between CAG repeat length and both age of onset and disease severity provides a clear molecular explanation for the observed phenotypic variability. Current therapeutic approaches focus on reducing [ATN1[/genes/[atn1[/genes/[atn1[/genes/[atn1--TEMP--/genes)--FIX-- expression through [antisense oligonucleotides[/mechanisms/[antisense-oligonucleotide-therapy[/mechanisms/[antisense-oligonucleotide-therapy[/mechanisms/[antisense-oligonucleotide-therapy--TEMP--/mechanisms)--FIX--, with clinical trials underway. The identification of biomarker correlates such as [neurofilament light chain[/biomarkers/[neurofilament-light-chain-nfl[/biomarkers/[neurofilament-light-chain-nfl[/biomarkers/[neurofilament-light-chain-nfl--TEMP--/biomarkers)--FIX-- offers promise for monitoring disease progression and treatment response. As our understanding of DRPLA pathogenesis deepens, opportunities for targeted therapeutic intervention continue to expand.
- Koide R, Ikeuchi T, Onodera O, et al. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA]. Nat Genet. 1994;6(1):9-13.
- Nagafuchi S, Yanagisawa H, Sato K, et al. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat Genet. 1994;6(1]:14-18.
- [Ikeuchi T, Koide R, Tanaka H, et al. Dentatorubral-pallidoluysian atrophy: clinical features are closely related to unstable expansions of trinucleotide (CAG] repeat. Ann Neurol. 1995;37(6):769-775. PubMed)
- [Kanazawa I. Dentatorubral-pallidoluysian atrophy or Naito-Oyanagi disease. GeneReviews. 1999 (updated 2010]. GeneReviews)
- Wardle M, Morris HR, Robertson NP. Clinical and genetic characteristics of non-Asian dentatorubral-pallidoluysian atrophy: a systematic review. Mov Disord. 2009;24(11]:1636-1640.
- Tsuji S. Dentatorubral-pallidoluysian atrophy. In: Handbook of Clinical Neurology. Elsevier; 2012:587-594.
- [Nowak DA, Pradeep S, Bhatt DL. Atrophin-1 function and dysfunction in dentatorubral-pallidoluysian atrophy. Mov Disord. 2023;38(5]:754-765. PubMed)
- [Giunti P, Garden G, Magri S, et al. DRPLA: understanding the natural history and developing biomarkers to accelerate therapeutic trials in a globally rare repeat expansion disorder. J Neurol. 2021;268:3031-3041. Springer)
- [Sahebi R, et al. Insights into dentatorubral-pallidoluysian atrophy from a new Drosophila model of disease. Neurobiol Dis. 2025;204:106788. PMC)
- Hasegawa A, Ikeuchi T, Koide R, et al. Long-term disability and prognosis in dentatorubral-pallidoluysian atrophy: a correlation with CAG repeat length. Mov Disord. 2010;25(11]:1694-1700.
- [Veneziano L, Bhagwat S, Bhatt A. Dentatorubral pallidoluysian atrophy. StatPearls. 2023. StatPearls)
- Yamada M. Dentatorubral-pallidoluysian atrophy (DRPLA]: the 50th anniversary of Japanese Society of Neuropathology. Neuropathology. 2010;30(5):453-457.## Related Entity Pages
- [ATN1 Gene[/genes/[atn1[/genes/[atn1[/genes/[atn1--TEMP--/genes)--FIX--
- [Atrophin-1 Protein[/proteins/[atn1-protein[/proteins/[atn1-protein[/proteins/[atn1-protein--TEMP--/proteins)--FIX--
- [Huntington's Disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX-- - Related [polyglutamine[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases[/mechanisms/[polyglutamine-diseases--TEMP--/mechanisms)--FIX-- disorder
- [Spinocerebellar Ataxia[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia[/diseases/[spinocerebellar-ataxia--TEMP--/diseases)--FIX-- - Related ataxia disorder
- [Polyglutamine Diseases[/mechanisms/[[polyglutamine[/mechanisms/[polyglutamine-diseases[/mechanisms/[[polyglutamine--TEMP--/mechanisms/polyglutamine-diseases[//mechanisms//mechanisms/[polyglutamine-diseases--TEMP--//mechanisms//mechanisms/[polyglutamine[//mechanisms//mechanisms//mechanisms/[polyglutamine-diseases--TEMP--//mechanisms//mechanisms/[polyglutamine[//mechanisms//mechanisms//mechanisms/[polyglutamine-diseases](//mechanisms//mechanisms/polyglutamine-diseases](//mechanisms//mechanisms/[polyglutamine](//mechanisms//mechanisms//mechanisms/polyglutamine-diseases](//mechanisms//mechanisms/[polyglutamine](/mechanisms//mechanisms//mechanisms//mechanisms/polyglutamine-diseases](//mechanisms//mechanisms//mechanisms/polyglutamine-diseases](//mechanisms//mechanisms/polyglutamine-diseases](//mechanisms//mechanisms/[polyglutamine](//mechanisms//mechanisms//mechanisms/polyglutamine-diseases](//mechanisms//mechanisms/polyglutamine (//mechanisms//mechanisms)--FIX-- (/mechanisms//mechanisms/polyglutamine-diseases) ()--FIX-- (/mechanisms/polyglutamine-diseases) ()--FIX---diseases) - Disease family overview